Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease

Open access
Taylor, Raymond, Kotian, Pravin, Warren, Travis, Panchal, Rekha, Bavari, Sina, Julander, Justin, Dobo, Sylvia, Rose, Angela, El-Kattan, Yahya, Taubenheim, Brian, Babu, Yarlagadda, Sheridan, William P.·2016·Journal of Infection and Public Health

Abstract

The adenosine nucleoside analog BCX4430 is a direct-acting antiviral drug under investigation for the treatment of serious and life-threatening infections from highly pathogenic viruses, such as the Ebola virus. Cellular kinases phosphorylate BCX4430 to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug’s monophosphate nucleotide into the growing RNA chain, causing premature chain termination. BCX4430 is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV and SARS-CoV. In vivo, BCX4430 is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, BCX4430 has demonstrated pronounced efficacy. In experiments conducted in several models, both a reduction in the viral load and an improvement in survival were found to be related to the dose of BCX4430. A Phase 1 clinical trial of intramuscular administration of BCX4430 in healthy subjects is currently ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jiph.2016.04.002

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 177

Metadata

Authors
Taylor, R., Kotian, P., Warren, T., Panchal, R., Bavari, S., Julander, J., Dobo, S., Rose, A., El-Kattan, Y., Taubenheim, B., Babu, Y., & Sheridan, W. P.
Venue
Journal of Infection and Public Health
Publisher
Elsevier BV
Published
2016-05
Volume
9
Issue
3
Pages
220-226
ISSN
1876-0341 (ISSN-L)
OpenAlex
W2337422248
Cited by
177
References
1
FWCI
17.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. https://app.cochat.ai/papers/10.1016/j.jiph.2016.04.002
The paper
Taylor, R., Kotian, P., Warren, T., Panchal, R., Bavari, S., Julander, J., Dobo, S., Rose, A., El-Kattan, Y., Taubenheim, B., Babu, Y., & Sheridan, W. P. (2016). BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. Journal of Infection and Public Health. https://doi.org/10.1016/j.jiph.2016.04.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.